United Therapeutics' Unituxin Disappoints In SCLC
Impact Likely Minimal On Company's Growth
Targeting gangliosides expressed on SCLC tumors has been explored by United Therapeutics in the Phase II/III DISTINCT study, but top-line results show no effect on overall survival.
You may also be interested in...
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
The Phase III failure of esuberaprost combined with Tyvaso in pulmonary arterial hypertension has prompted United Therapeutics to stop developing a therapy that was already facing an uphill battle for potentially meager returns.
Opdivo failed to meet an overall survival endpoint in a Phase III confirmatory study in small-cell lung cancer. But several analysts think Bristol will keep the SCLC labeling obtained in August due to lack of treatment options for these patients.